Publications by authors named "Adalgisa P Ferreira"
Article Synopsis
- - Chronic hepatitis B affects about 290 million people globally, leading to serious issues like cirrhosis and liver cancer, but only 10% of those infected are diagnosed.
- - In Brazil, most areas have low rates of HBV infection, but some regions have higher carrier frequencies, and many infected individuals remain unidentified and untreated.
- - The Brazilian Society of Infectious Diseases and the Brazilian Society of Hepatology created a guideline covering diagnostic procedures, treatment options, and management strategies for special groups like pregnant women and immunosuppressed patients, addressing delta infection as well.
Background: Hepatitis C is an important health problem. In Brazil, 1-2 million people are infected. Despite this expressive number, and the availability of very successful treatment, many patients remained undiagnosed mainly because of the asymptomatic nature of the infection.
View Article and Find Full Text PDFBackground: Few studies have evaluated the histological aspects of hepatitis C virus (HCV) infection in hemodialysis patients and the factors related to the progression of hepatic fibrosis in this population have not been defined.
Aim: To evaluate the influence of host-related factors on the fibrosis progression in end-stage renal disease (ESRD) patients with HCV infection.
Methods: HCV-infected ESRD patients who submitted to liver biopsy were included.
Background: Interferon monotherapy significantly reduces the chronicity rate of acute hepatitis C in nonuremic patients. In this clinical study, we evaluated the efficacy and tolerance of interferon-alpha therapy for acute hepatitis C in hemodialysis patients.
Methods: Patients with acute hepatitis C, established on the basis of seroconversion to anti-hepatitis C virus and the presence of hepatitis C virus RNA, received a low dose of interferon-alpha (3 MU three times per week) for 12 months or a high dose (5 MU three times per week, preceded by a daily induction dose) for 6 months.
Background: Patients with end-stage renal disease (ESRD) show a high prevalence of hepatitis C, with a negative impact on the survival on hemodialysis and after renal transplantation. We evaluated the efficacy and tolerance of interferon-alpha (IFN-alpha) in HCV-infected ESRD patients on dialysis.
Methods: Forty-six HCV-RNA-positive ESRD patients were studied.
The distribution of hepatitis C virus (HCV) genotypes in patients on hemodialysis and in kidney transplant recipients was compared with that observed in a control group composed of HCV-infected individuals from the general population. A total of 340 patients were included in the study: 46 with end-stage renal disease on regular hemodialysis treatment, 22 kidney transplant recipients and 272 controls matched for sex and age at a 4:1 ratio (controls to patient). HCV genotype was determined by sequencing of the 5' untranslated region of the HCV genome.
View Article and Find Full Text PDF